CERo Therapeutics Advances CER-1236 Clinical Trial in Hematologic Malignancies
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 18 hours ago
0mins
Source: Newsfilter
- Clinical Trial Progress: CERo Therapeutics has dosed the second patient (fifth overall) in its CER-1236 clinical trial focused on acute myeloid leukemia (AML), with plans to expand into myelodysplastic syndromes (MDS) and myelofibrosis (MF), demonstrating the company's ongoing innovation in hematologic malignancies.
- Safety Monitoring Results: Over seven days of follow-up after the second patient's infusion, no cases of cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) were observed, and no dose-limiting toxicities occurred during the 28-day assessment window, indicating good safety for CER-1236.
- Efficacy Observations: A patient who received four CER-1236 infusions over five months achieved 72 consecutive days of platelet transfusion independence, showcasing the potential efficacy of this therapy in AML treatment and further supporting the expansion of enrollment into MDS and MF patients.
- Strategic Expansion Plans: CERo plans to include transfusion-dependent MDS (TD-MDS) and high-risk MDS (HR-MDS) patients in its clinical trial, aiming to address the significant unmet needs of these patient populations, reflecting the company's strong commitment to innovative cell therapies.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
